Delivery Order SPE2DB22D2206-SPE2DB22FEE77
- Not listed
- This federal contract award, valued at $89,155.06, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a delivery order for 4,567,951,671 units of the medication REVLIMID 25 MG CAPSULE 100S, with a performance period through May 7, 2025. The contract is a firm fixed-price, non-set-aside award. Amerisourcebergen Drug Corp holds a significant $999,999,999.00 Indefinite Delivery...
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $89,155.06 firm fixed-price contract is for the supply of REVLIMID 25 MG CAPSULE 100S, a specialty medication, to support military healthcare programs. The contract has an ultimate completion date of January 10, 2025. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop...
- This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, provides for the delivery of REVLIMID 10 MG CAPSULE 28S medical products to the Defense Logistics Agency (DLA). The contract has a total ceiling value of $49,926.80 and runs through February 2025. It is a firm fixed-price Delivery Order contract, with no set-aside designation. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical valued at...
- This federal contract award is for the delivery of the pharmaceutical drug Revlimid (10 mg capsule, 28-count) to the Defense Logistics Agency (DLA). The $23,330.28 firm fixed-price delivery order was awarded to AmerisourceBergen Drug Corp's Corporate Office division, a major pharmaceutical distributor. The contract, which has no set-aside designation, has a completion date of June 5, 2024. AmerisourceBergen holds a $999,999,999.00 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide Revlimid 25 mg capsule medication. The $20,562.98 contract has an ultimate completion date of April 24, 2024 and was awarded on April 3, 2024. Amerisourcebergen Drug Corp is the prime contractor and there is no set-aside designation. This delivery order is part of a larger indefinite delivery contract (IDC) awarded to...
- This federal contract award is a delivery order with a ceiling value of $24,963.40 issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of REVLIMID 5 MG CAPSULE 28S, a pharmaceutical product, with a period of performance through November 2024. The contract is a firm fixed-price arrangement and does not have a set-aside designation, indicating open competition....
- This federal contract award, valued at $83,322.49, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order for the supply of REVLIMID 5 MG CAPSULE 100S, a prescription medication. The contract has an ultimate completion date of January 13, 2023 and is a Firm Fixed Price arrangement. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, a leading global pharmaceutical sourcing and distribution services company. The contract is a firm fixed price delivery order for the supply of REVLIMID 10 MG Capsules. The award has a ceiling value of $105,612.88 and an ultimate completion date of May 3, 2024. Amerisourcebergen Drug Corp is the prime contractor and there is no set-aside...
- The U.S. government awarded a Firm Fixed Price delivery order contract to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of REVLIMID 10 MG CAPSULE 100S. The contract, valued at $105,150.98, has an ultimate completion date of July 14, 2025 and was awarded on June 20, 2025. The contract is funded by the Defense Logistics Agency (DLA), a defense agency. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support...
- This federal contract award, with an ID of SPE2DB22D2206|SPE2DB25FGP81, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Revlimid 5 mg capsules, with a ceiling value of $89,155.06 and a performance period extending through May 7, 2025. The contract is a Firm Fixed Price Delivery Order, with no set-aside designation, indicating open competition....
- SPE2DB22D2206Indefinite Delivery Contract
- SPE2DB22D2206-SPE2DB22FEE77Delivery Order
This is a federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, by the Defense Logistics Agency (DLA). The contract, valued at $77,433.35, is for the delivery of Revlimid 25 mg capsules. It is a firm-fixed-price delivery order contract with an ultimate completion date of August 29, 2022. The contract is not designated as a set-aside. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. This contract award demonstrates Amerisourcebergen's role as a key vendor for federal healthcare programs, particularly within military and veterans' healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $77.4k | 8/8/22 |